SUPPLEMENTARY INFORMATION

Surface charge tunable catanionic vesicles based on serine-derived surfactants as efficient nanocarriers for the delivery of the anticancer drug doxorubicin

Raquel C. F. Gonçalves Lopes,[†a,b] Oscar F. Silvestre,[†a] Ana Rita Faria,[a] M. Luísa do Vale,[c] Eduardo F. Marques *[b] and Jana B. Nieder *[a]

[a]*Department of Nanophotonics, Ultrafast Bio- and Nanophotonics group, INL - International Iberian Nanotechnology Laboratory, Av. Mestre José Veiga s/n, 4715-330 Braga, Portugal.*
[*]*jana.nieder@inl.int*
[b]*CIQUP, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre s/n, 4169-007 Porto, Portugal.*
[*]*efmarque@fc.up.pt*
[c]*LAQV-REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal.*
† These authors contributed equally to this work.



Fig. S1. Size distribution plot of the spontaneous (non-extruded) and empty (non-DOX loaded) 16Ser/8-8Ser vesicles showing very polydisperse populations for both the (0.20) and (0.58) systems.



Fig. S2. Viability of A549 cells after 72 h of incubation with neat serine-based surfactants 16Ser and 8-8Ser.



Fig. S3. DOX sample suspensions fluorescence of both drug loaded 16Ser/8-8Ser vesicles after washing compared to free DOX at 100 µM concentration.



Fig. S4. Normalized fluorescence spectra of free DOX and sample suspensions of both DOX loaded 16Ser/8-8Ser vesicles after washing.



Fig. S5. Size distribution plot of the spontaneous (non-extruded) DOX-loaded 16Ser/8-8Ser vesicles for both the (0.20) and (0.58) systems.



Fig. S6. Release profiles of Doxorubicin (DOX) from (a) DOX@16Ser/8-8Ser (0.20) and (b) DOX@16Ser/8-8Ser (0.58) in pH 5.0 and pH 7.4 PBS solutions at 37°C, respectively.